Background: A problem likely to be encountered in any cancer immunotherapy based on vaccination with a single protein or peptide is variation in the host response. A particularly informative example is provided by the two oncogenic proteins, one intracellular and the other extracellular, encoded by the avian erythroblastosis virus (AEV), homologs of the thyroid hormones receptor (THsR) and the epithelial growth factor receptor (EGFR), respectively. Materials and Methods: Antibodies to these two proteins were assayed by radioimmune precipitation (RIP) in sera from MHC-congenic rats immunized by virally induced tumors.
INTRODUCTION
Hope is growing for cancer immunotherapy in general (1, 2) and for that involving the epithelial growth factor (EGF) receptor (3) (4) (5) in particular. This glycoprotein, which is encoded by the c-erb B gene, is a particularly attractive target because it is exposed on the cell surface and is overexpressed in certain tumors (6) . As has been experienced with other single-protein or single-peptide vaccines (7, 8) , some individuals are likely to be unable to respond, and this will be due in part to the presence of nonresponder MHC alleles.
A well-established animal model for examining this possibility is the rat. Neonatal rats injected with fibroblasts transformed by avian erythroblastosis virus (AEV) develop tumors at the site of innoculation in 50-60% of the animals within 6 -8 weeks (9) . FL 
MATERIALS AND METHODS
The animals used are listed in Table 1 , together with their origins and allele assignments at the major histocompatibility loci RG1.A and RG1.B (11) . The MHC-congenic PVG strains were purchased from Olac (London, United Kingdom), and the F334 strain of Fisher rat obtained from the Imperial Cancer Research Fund breeding colony.
Tumor induction and the preparation of antiserum were as described (9) . Clone ATla of Fisher fibroblasts transformed by avian erythroblastosis virus (AEV) were innoculated intraperitoneally (5 X 106 cells) into 7-to 14-day-old Fisher X Lewis Fl hybrid rats. The animals that developed tumors were bled by cardiac puncture [8] [9] [10] [11] [12] weeks after the innoculation.
Individual sera were analyzed by radioim- Figure 2 shows the measured levels of antibodies. Measurements did not vary significantly between groups for the anti-erb A antibody, but clearly did so for the anti-erb B antibody. The first group of sera, from RT1l/c rats, was taken as standard, from which the second, third, and sixth groups (RT1l/u, RTII/rl, and RT1a/l, respectively) did not differ significantly. The fourth group (RTl1/") was significantly lower (t = 4.57, p < 0.0001); as the standard deviations of the two groups were significantly different, a nonparametric statistical analysis was also applied (Mann-Whitney p = 0.0005). The fifth group (RTlI/a) was also significantly lower (t = 1.89, p = 0.032), but, nevertheless, still significantly higher than the fourth group (t = 3.36, p = 0.002).
The fifth group (RTli/a) was significantly lower (t = 2.10, p = 0.040) than the third group (RG11/ri). This comparison is a particularly important because it provides information on the role of the class II RG1.B locus in the control of this response. These two groups differ at RG1.B but not at RG1.A, suggesting that the substitution of RG1.Ba for RG1.BC is responsible for this reduction. We 
